Haemonetics (HAE) AI Stock Analysis

• Market Cap: $3.54B
• Dividend Yield: N/A
• Average Volume (3M): 638.03K
• Price to Earnings (P/E): 22.1
• Beta (1Y): 0.53
• Revenue Growth: -2.45%
• EPS Growth: 41.50%
• Country: US
• Employees: 3,657
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 1.27
• Shares Outstanding: 46,809,673
• 10 Day Avg. Volume: 464,510
• 30 Day Avg. Volume: 638,033
• PEG Ratio: 0.44
• Price to Book (P/B): 3.87
• Price to Sales (P/S): 2.34
• P/FCF Ratio: 22.33
• Enterprise Value/Market Cap: 0.91
• Enterprise Value/Revenue: 2.43
• Enterprise Value/Gross Profit: 4.14
• Enterprise Value/Ebitda: 8.60
• 1Y Price Target: $88.86
• Price Target Upside: 12.74% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 8
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 74 Outperform
• Price Target: $94.00 ▲(19.26% Upside)

The score is driven primarily by solid financial quality (strong margins and accelerating free cash flow) and supportive technical momentum (price above key moving averages with positive MACD). Offsetting factors include modestly elevated valuation (P/E ~24.5), leverage risk, and the ongoing impact of portfolio transitions that pressure reported revenue despite improved guidance.

Positive Factors

Gross Margin Expansion

Sustained adjusted gross margins (60.5% in Q2) indicate durable pricing power and efficient cost structure. High margins support reinvestment in R&D and commercialization, enhance operating leverage, and underpin long-term profitability even if revenue growth fluctuates.

Cash Generation

Robust cash generation (35.37% FCF growth TTM and materially improved operating cash flow) provides strategic flexibility for M&A, debt reduction, capex, and buybacks. Strong cash conversion underpins balance sheet resilience and funds growth without dilutive financing.

Strategic Portfolio Expansion

The Vivasure acquisition adds a bioabsorbable large-bore vessel closure technology and expands presence in structural heart and endovascular markets. This diversifies and moves the company into faster-growing adjacencies, leveraging Haemonetics' commercial scale for durable revenue opportunities.

Negative Factors

Leverage Risk

A relatively high debt-to-equity (1.44 TTM) heightens interest rate and refinancing sensitivity, limiting financial flexibility. Elevated leverage can crowd out discretionary investment, raise fixed costs, and amplify downside risk if organic growth or cash generation weakens.

Reported Revenue Decline

Reported revenue has declined (Q2 -5%, TTM negative growth) driven by portfolio transitions. Even with strong organic ex-CSL growth, continuing reported declines complicate forecasting, could depress long-term top-line momentum, and require sustained execution to restore visible growth.

Acquisition Execution & Contingent Risk

Vivasure deal includes up to €85M contingent payments and hinges on regulatory outcomes (FDA review). Realizing value depends on clinical/regulatory success and integration; contingent liabilities and timing uncertainty raise execution risk and potential cash outflows.

Haemonetics Business Overview & Revenue Model

Company Description

Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; and Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

How the Company Makes Money

Haemonetics generates revenue through several key streams including the sale of medical devices and consumables for blood collection and processing, software solutions for blood management, and services related to these products. The company earns significant income from its hematology products, particularly those used in blood and plasma centers. Additionally, Haemonetics has established partnerships with various healthcare organizations, enhancing its market reach and operational capabilities. Revenue is further supported by ongoing service agreements, maintenance contracts, and training services for healthcare providers, which create a recurring revenue model.

Haemonetics Financial Statement Overview

Summary

Haemonetics demonstrates strong profitability and cash flow management with a consistent gross profit margin and robust cash conversion efficiency. However, the company faces challenges with declining revenue growth and high leverage.

Income Statement

Haemonetics shows strong profitability with a consistent gross profit margin around 56% in TTM, and a stable net profit margin of 12.1%. However, the revenue growth rate has declined by 1.1% in TTM, indicating a potential slowdown in sales growth. EBIT and EBITDA margins remain healthy, reflecting efficient operations.

Balance Sheet

The company has a high debt-to-equity ratio of 1.39 in TTM, suggesting significant leverage, which could pose risks if not managed carefully. However, the return on equity is robust at 18.7%, indicating effective use of equity to generate profits. The equity ratio is moderate, reflecting a balanced asset structure.

Cash Flow

Haemonetics demonstrates strong cash flow management with a 32.8% growth in free cash flow in TTM. The operating cash flow to net income ratio is 0.43, and the free cash flow to net income ratio is 0.84, indicating good cash conversion efficiency. This positions the company well for future investments and debt servicing.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.33B	1.36B	1.31B	1.17B	993.20M	870.46M
Gross Profit	779.57M	778.55M	711.91M	622.87M	530.77M	428.45M
EBITDA	375.13M	355.99M	295.45M	252.01M	191.72M	184.38M
Net Income	168.19M	167.68M	117.56M	115.40M	43.38M	79.47M
Balance Sheet
Total Assets	2.44B	2.45B	2.20B	1.93B	1.86B	1.82B
Cash, Cash Equivalents and Short-Term Investments	296.43M	306.76M	178.80M	284.47M	259.50M	192.31M
Total Debt	1.22B	1.22B	807.79M	765.89M	780.78M	778.28M
Total Liabilities	1.59B	1.63B	1.24B	1.12B	1.11B	1.09B
Stockholders Equity	849.17M	820.84M	959.96M	818.00M	749.42M	731.67M
Cash Flow
Free Cash Flow	256.08M	142.45M	115.45M	162.87M	75.75M	71.77M
Operating Cash Flow	289.04M	181.72M	181.75M	273.06M	172.26M	108.81M
Investing Cash Flow	-62.80M	-161.90M	-322.39M	-143.79M	-86.34M	-425.44M
Financing Cash Flow	-229.06M	108.82M	38.16M	-100.36M	-15.75M	367.45M

Haemonetics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 78.82
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HAE, the sentiment is Negative. The current price of 78.82 is below the 20-day moving average (MA) of 80.76, above the 50-day MA of 77.58, and above the 200-day MA of 65.81, indicating a neutral trend. The MACD of 0.65 indicates Positive momentum. The RSI at 37.74 is Neutral, neither overbought nor oversold. The STOCH value of 26.35 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HAE.

Haemonetics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MMSI	77 Outperform	$4.85B	41.84	8.30%	―	11.49%	-2.89%
LMAT	75 Outperform	$1.94B	36.77	15.02%	0.95%	13.07%	27.98%
HAE	74 Outperform	$3.54B	22.09	19.47%	―	-2.45%	41.50%
TFX	61 Neutral	$4.55B	-14.01	-7.90%	1.11%	5.43%	-245.18%
ICUI	61 Neutral	$3.67B	-477.71	-0.35%	―	-0.81%	93.27%
QDEL	54 Neutral	$2.33B	-2.02	-44.21%	―	-3.43%	38.98%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Haemonetics Corporate Events

Haemonetics acquires Vivasure to expand structural heart portfolio

On January 9, 2026, Haemonetics Corporation announced it had acquired Vivasure Medical Limited in a deal comprising an upfront cash payment of €100 million—about €52 million net of prior Haemonetics investments and loans—and up to an additional €85 million in milestone-based contingent consideration, financed entirely with cash on hand. The acquisition gives Haemonetics ownership of Vivasure’s PerQseal Elite bioabsorbable large-bore vessel closure technology, which has demonstrated strong safety and performance data, received CE Mark approval in Europe in 2025 and is under U.S. FDA review, strengthening Haemonetics’ portfolio of closure devices, deepening its presence in the fast-growing structural heart and endovascular markets, and positioning the company to leverage its commercial scale and operational synergies to increase its leadership and value proposition for physicians and hospitals.

The most recent analyst rating on (HAE) stock is a Buy with a $90.00 price target. To see the full list of analyst forecasts on Haemonetics stock, see the HAE Stock Forecast page.